197 related articles for article (PubMed ID: 26876916)
1. Therapeutic potential of chalcones as cardiovascular agents.
Mahapatra DK; Bharti SK
Life Sci; 2016 Mar; 148():154-72. PubMed ID: 26876916
[TBL] [Abstract][Full Text] [Related]
2. Chalcones and their therapeutic targets for the management of diabetes: structural and pharmacological perspectives.
Mahapatra DK; Asati V; Bharti SK
Eur J Med Chem; 2015 Mar; 92():839-65. PubMed ID: 25638569
[TBL] [Abstract][Full Text] [Related]
3. Chalcone scaffolds as anti-infective agents: structural and molecular target perspectives.
Mahapatra DK; Bharti SK; Asati V
Eur J Med Chem; 2015 Aug; 101():496-524. PubMed ID: 26188621
[TBL] [Abstract][Full Text] [Related]
4. Anti-cancer chalcones: Structural and molecular target perspectives.
Mahapatra DK; Bharti SK; Asati V
Eur J Med Chem; 2015 Jun; 98():69-114. PubMed ID: 26005917
[TBL] [Abstract][Full Text] [Related]
5. Advances in chalcones with anticancer activities.
Karthikeyan C; Moorthy NS; Ramasamy S; Vanam U; Manivannan E; Karunagaran D; Trivedi P
Recent Pat Anticancer Drug Discov; 2015; 10(1):97-115. PubMed ID: 25138130
[TBL] [Abstract][Full Text] [Related]
6. Perspectives of medicinally privileged chalcone based metal coordination compounds for biomedical applications.
Mahapatra DK; Bharti SK; Asati V; Singh SK
Eur J Med Chem; 2019 Jul; 174():142-158. PubMed ID: 31035237
[TBL] [Abstract][Full Text] [Related]
7. Current Discovery Progress of Some Emerging Anti-infective Chalcones: Highlights from 2016 to 2017.
Mahapatra DK; Ghorai S; Bharti SK; Patil AG; Gayen S
Curr Drug Discov Technol; 2020; 17(1):30-44. PubMed ID: 30033873
[TBL] [Abstract][Full Text] [Related]
8. [Chalcones (1,3-diarylpropen-1-ones) and their analogs as potential therapeutic agents in cardiovascular system diseases].
Opletalová V; Jahodár L; Jun D; Opletal L
Ceska Slov Farm; 2003 Jan; 52(1):12-9. PubMed ID: 12685329
[TBL] [Abstract][Full Text] [Related]
9. Recent developments of chalcones as potential antibacterial agents in medicinal chemistry.
Dan W; Dai J
Eur J Med Chem; 2020 Feb; 187():111980. PubMed ID: 31877539
[TBL] [Abstract][Full Text] [Related]
10. Recent developments in biological aspects of chalcones: the odyssey continues.
Rani A; Anand A; Kumar K; Kumar V
Expert Opin Drug Discov; 2019 Mar; 14(3):249-288. PubMed ID: 30773996
[TBL] [Abstract][Full Text] [Related]
11. Structural Modifications on Chalcone Framework for Developing New Class of Cholinesterase Inhibitors.
George G; Koyiparambath VP; Sukumaran S; Nair AS; Pappachan LK; Al-Sehemi AG; Kim H; Mathew B
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328542
[TBL] [Abstract][Full Text] [Related]
12. [New cardiovascular-active drugs].
Bölter C
Z Arztl Fortbild (Jena); 1984; 78(19):797-800. PubMed ID: 6506791
[No Abstract] [Full Text] [Related]
13. An updated patent review of therapeutic applications of chalcone derivatives (2014-present).
Kar Mahapatra D; Asati V; Bharti SK
Expert Opin Ther Pat; 2019 May; 29(5):385-406. PubMed ID: 31030616
[TBL] [Abstract][Full Text] [Related]
14. Chalcone derivatives and their antibacterial activities: Current development.
Xu M; Wu P; Shen F; Ji J; Rakesh KP
Bioorg Chem; 2019 Oct; 91():103133. PubMed ID: 31374524
[TBL] [Abstract][Full Text] [Related]
15. Heterocyclic chalcone analogues as potential anticancer agents.
Sharma V; Kumar V; Kumar P
Anticancer Agents Med Chem; 2013 Mar; 13(3):422-32. PubMed ID: 22721390
[TBL] [Abstract][Full Text] [Related]
16. Chalcones derivatives acting as cell cycle blockers: potential anti cancer drugs?
Boumendjel A; Ronot X; Boutonnat J
Curr Drug Targets; 2009 Apr; 10(4):363-71. PubMed ID: 19355861
[TBL] [Abstract][Full Text] [Related]
17. Potential pharmacological uses of chalcones: a patent review (from June 2011 - 2014).
Matos MJ; Vazquez-Rodriguez S; Uriarte E; Santana L
Expert Opin Ther Pat; 2015 Mar; 25(3):351-66. PubMed ID: 25598152
[TBL] [Abstract][Full Text] [Related]
18. Trends in utilization of the pharmacological potential of chalcones.
Batovska DI; Todorova IT
Curr Clin Pharmacol; 2010 Feb; 5(1):1-29. PubMed ID: 19891604
[TBL] [Abstract][Full Text] [Related]
19. The utility of cardiovascular drugs in the treatment of cerebrovascular disease.
Bösel J; Amiri H
Curr Opin Investig Drugs; 2010 Sep; 11(9):1015-24. PubMed ID: 20730696
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P450-mediated cardiovascular drug interactions.
Scheen AJ
Expert Opin Drug Metab Toxicol; 2011 Sep; 7(9):1065-82. PubMed ID: 21810031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
